Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against Candida albicans and Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal Effect
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Drug exposure or pharmacodynamic breakpoints refer to a magnitude of drug exposure which separates a population into groups with high and low probabilities of attaining a desired outcome. We used a pharmacodynamic model of disseminated candidiasis to define an in vivo drug exposure breakpoint for flucytosine (5FC) against Candida albicans. The results were bridged to humans by using population pharmacokinetics and Monte Carlo simulation. An in vivo drug exposure breakpoint for 5FC was apparent when serum levels were above the MIC for 45% of the dosing interval. The Monte Carlo simulations suggested that using a human dose of 100 mg/kg of body weight/day in four divided doses, 5FC resistance was defined at an MIC of 32 mg/liter. Target attainment rates following administration of 25, 50, and 100 mg/kg/day were similar, suggesting that the use of a lower dose of 5FC is possible. Using six isolates of C. albicans with MICs ranging from 0.06 to >64 mg/liter, we also explored the influence that the MIC, the fraction of the dosing interval that the serum levels of 5FC remained above the MIC (T>MIC), the 5FC resistance genotype, and the in vivo growth rate had on the response to 5FC. The MIC and T>MIC were both critical measures affecting the generation of a drug effect but had no bearing on the magnitude of the maximal kill induced by 5FC. The in vivo growth rate was a critical additional determinant of the exposure-response relationship. There was a relationship between the 5FC resistance genotype and the exposure-response relationship.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855 · cited 1×
“This is probably due to a range of factors, related to both the host and the invading pathogen, which may obscure any predictive outcome signal which emanates from the MIC (21).”
BackgroundSelf-citationAntifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444 · cited 1×
“Failure to achieve adequate drug exposure to a fungal pathogen is likely to be an important cause of a suboptimal outcome (22).”
BackgroundSelf-citationEffect of Growth Rate on Resistance of Candida albicans Biofilms to Antifungal Agents
Baillie, G. S., & Douglas, L. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.8.1900 · Cited by 234
Francis, P., & Walsh, T. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.6.1003 · Cited by 232
Self-citationAndes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3165-3169.2003 · Cited by 231 · cited 1×
“dt K g 1 X(1) POPMAX X(1) ( 2 ) where X(1) is the population density at a given time, Kg is the maximum growth rate constant, and POPMAX is the theoretical maximum fungal density.”
BackgroundMolecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans
Hope, W. W., Tabernero, L., Denning, D. W., & Anderson, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4377-4386.2004 · Cited by 160 · cited 3×
“Flucytosine (5FC) is a fluorinated pyrimidine which acts as a subversive substrate within the pyrimidine salvage pathway (16, 17).”
BackgroundSelf-citation
Cited by
Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 716
Self-citationAntifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490
Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints
Verweij, P. E., Howard, S. J., Melchers, W. J. G., & Denning, D. W. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.09.002 · Cited by 260
Self-citationTherapeutic Drug Monitoring of Antifungals: Pharmacokinetic and Pharmacodynamic Considerations
Smith, J., & Andes, D. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318167d0e0 · Cited by 156
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
“…of escalating concentrations of flucytosine on efficacy 10 Cite this article as Cold Spring Harb Perspect Med 2015;5:a019653 w w w .p er sp ec ti ve si n m ed ic in e. o rg against Candida (Turnidge et al. 1994; Andes and van Ogtrop 2000; Lewis et al. 2000; Ernst et al. 2002b; Hope et al. 2006).”
Background
Metadata
- Authors
- Hope, W. W., Warn, P. A., Sharp, A., Howard, S., Kasai, M., Louie, A., Walsh, T. J., Drusano, G. L., & Denning, D. W.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-11
- Volume
- 50
- Issue
- 11
- Pages
- 3680-3688
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2131042247
- Cited by
- 49
- References
- 6
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against Candida albicans and Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal Effect. https://app.cochat.ai/papers/10.1128/aac.00369-06
- The paper
- Hope, W. W., Warn, P. A., Sharp, A., Howard, S., Kasai, M., Louie, A., Walsh, T. J., Drusano, G. L., & Denning, D. W. (2006). Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against Candida albicans and Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal Effect. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00369-06
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.